ArticleCancer heterogeneity and plasticity2026
Hippo-YAP/TAZ signaling in gastric cancer: orchestrating epithelial-stromal heterogeneity, plasticity, and therapy resistance.
Article in Cancer heterogeneity and plasticity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Gastric cancer is a lethal malignancy with highly variable clinical behavior, reflecting both inter-tumor diversity and marked heterogeneity within individual lesions. Large-scale genomics data (including TCGA and ACRG) has delineated recurring molecular subtypes, while expression- and immunohistochemistry-based schemes provide clinically practical surrogates. However, single-cell and spatial profiling reveal that most tumors comprise multiple malignant epithelial states alongside diverse cancer-associated fibroblast (CAF) and immune programs that vary spatially, evolve during progression, and are remodeled by therapy. The Hippo pathway effectors YAP and TAZ act as central integrators of oncogenic, inflammatory, and mechanical cues that coordinate these dynamic states. In gastric cancer, YAP/TAZ activity is enriched in diffuse/EMT-like and mesenchymal phenotypes, associates with peritoneal dissemination, and contributes to immune evasion and treatment resistance. Here, we link YAP/TAZ activity to gastric cancer subtype heterogeneity and emphasize two interconnected dimensions: (i) cell heterogeneity, encompassing coexisting epithelial lineage states and CAF subsets within tumors; and (ii) cell plasticity, highlighting reversible transitions that enable invasion, metastasis, and drug resistance. Finally, we propose a framework of YAP/TAZ-governed epithelial-stromal ecotypes and discuss implications for biomarkers and rational combination strategies incorporating Hippo-targeted agents with chemotherapy, stromal modulation, and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.